Incyte says Phase 1/2 data show 81% median bleed-rate cut with VWD drug latarcibart
PUBT · 1d ago
Share
Listen to the news
- Incyte disclosed Phase 1/2 multidose data for VGA039 (latarcibart) in von Willebrand disease, supporting ongoing pivotal Phase 3 development.
- Across 16 patients, median annualized bleeding rate fell 81% with once-monthly subcutaneous dosing; reductions were reported across all VWD types.
- Patients switching from VWF-containing IV prophylaxis saw 75%-100% bleed reductions, suggesting potential improvement versus current prophylactic practice.
- Safety profile appeared favorable; three treatment-related adverse events were reported, including Grade 2 headaches and a Grade 1 injection-site reaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713735007) on July 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved